Noll et al. [35] showed that MSCs derived from bone marrow in myeloma patients, expressed higher levels of the plasma cell-activating factor IL-6 and the osteoclast-activating factor receptor activator of nuclear factor-κB ligand (RANKL) [35]. Here, IL6 is linked to plasma cell myeloma.